

Appendix 3. Characteristics of Included Randomized, Controlled, Trials*

RCT	Topic	Intervention	Comparator	Number of Patients Randomized	JADAD Score
Carrieri 2014	Primary Care	Methadone maintenance therapy induction in Primary Care	Methadone maintenance therapy induction in Specialty Care	221	2
Fiellin 2001	Primary Care	Methadone maintenance therapy delivered by primary care physician	Methadone maintenance therapy delivered by a narcotic treatment program	46	3
Gibson 2003**	Primary Care	Buprenorphine in primary care	Buprenorphine in specialty care	115	2
O'Connor 1998	Primary Care	Buprenorphine delivered through primary care	Buprenorphine delivered in traditional drug treatment program	46	2
Rosenthal 2013**	Pharmacotherapy	Buprenorphine-naloxone	Placebo	287	3
Dunlop 2017*	Pharmacotherapy	Buprenorphine-naloxone	Waitlist	50	3
Sigmon 2016*	Pharmacotherapy	Buprenorphine-naloxone	Waitlist	50	1
Wilson 2010*	Pharmacotherapy	Methadone	Waitlist	319	3
Piralishvili 2015*	Pharmacotherapy	Buprenorphine-naloxone	Methadone	80	3
Neumann 2013*	Pharmacotherapy	Buprenorphine-naloxone	Methadone	54	2
Potter 2013*	Pharmacotherapy	Buprenorphine-naloxone	Methadone	1269	2
Coviello 2010*	Pharmacotherapy	Oral naltrexone	Treatment as usual	111	1
Krupitsky 2012*	Pharmacotherapy	Oral naltrexone+ Placebo implant	Placebo oral naltrexone + placebo implant	306	4

Krupitsky 2013*	Pharmacotherapy	Oral naltrexone+ Placebo guanfacine	Placebo oral naltrexone + placebo guanfacine	301	4
Mokri 2016*	Pharmacotherapy	Oral naltrexone	Buprenorphine/naloxone	129	5
Springer 2018*	Pharmacotherapy	Injectable naltrexone	Placebo	93	4
Bisaga 2015*	Pharmacotherapy (Cannabinoids)	Dronabinol	Placebo	60	3
Blondell 2010	Tapering (Duration of Therapy)	Buprenorphine-naloxone taper	Buprenorphine-naloxone stable	12	3
Fiellin 2014**	Tapering (Duration of Therapy)	Buprenorphine-naloxone taper	Buprenorphine-naloxone stable	113	3
Sees 2000**	Tapering (Duration of Therapy)	Methadone taper	Methadone stable	179	3
Marsch 2016	Tapering (Duration of Therapy)	Buprenorphine-naloxone 28-day taper	Buprenorphine-naloxone 56-day taper	53	4
Ling 2009	Tapering (Duration of Therapy)	Buprenorphine-naloxone 7-day taper	Buprenorphine-naloxone 28-day taper	516	2
Sigmon 2013	Tapering (Duration of Therapy)	Buprenorphine-naloxone 1-week taper or Buprenorphine-naloxone 2-week taper	Buprenorphine-naloxone 4-week taper	70	4
Abbott 1998	Psychosocial	Community Reinforcement Approach	Standard Care	180	2
Chawarski 2011	Psychosocial	Counseling + Methadone maintenance therapy	Methadone maintenance therapy	37	2

Fiellin 2006	Psychosocial	Enhanced Medical Management (45-minute counseling sessions)	Standard Management (20-minute sessions)	166	3
Gu 2013	Psychosocial	Counseling + Methadone maintenance therapy	Methadone maintenance therapy	288	2
Liu 2018*	Psychosocial	Counseling + Methadone maintenance therapy	Methadone maintenance therapy	125	3
Tetrault 2012	Psychosocial	Enhanced Medical Management (45-minute counseling sessions)	Standard Management (15-minute counseling sessions)	47	2
Weiss 2011	Psychosocial	Counseling (45-60 minutes)	Standard Management (15-20 minutes)	653	3
Bernstein 2005	Psychosocial	Motivational Interviewing	Standard Care	1175	5
Jaffray 2014	Psychosocial	Motivational Interviewing	Standard Care	542	2
Saunders 1995	Psychosocial	Motivational Interviewing	Education	122	0
Stein 2009	Psychosocial	Motivational Interviewing	Assessment	277	1
Abrahms 1979	Psychosocial	Cognitive Behavioral Therapy	Group Therapy	14	1
Fiellin 2013	Psychosocial	Physician Management + Cognitive Behavioral Therapy	Physician Management	141	3
Ling 2013	Psychosocial	Cognitive Behavioral Therapy	No Behavioral Therapy	104	3
Pan 2015*	Psychosocial	Cognitive Behavioral Therapy + Methadone maintenance therapy	Methadone maintenance therapy	240	3

Scherbaum 2005	Psychosocial	Methadone Maintenance Therapy + Group Cognitive Behavioral Therapy	Methadone maintenance therapy	73	3
Abbott 1998	Psychosocial	Methadone + Contingency Management	Methadone with Standard Counseling	166	2
Bickel 2008	Psychosocial	Contingency Management	Standard counseling	135	2
Brooner 2004	Psychosocial	Motivated Stepped Care	Standard Stepped Care	127	1
Chen 2013	Psychosocial	Contingency Management	Usual Care	246	1
Chopra 2009	Psychosocial	Medication contingency with community reinforcement approach	Standard care with counseling	120	2
Chutuape 1999	Psychosocial	Contingency Management	Standard Care	14	3
Chutuape 2001	Psychosocial	Contingency Management	Weekly draws for take-home doses (not contingent)	53	2
DeFulio 2012	Psychosocial	Contingency Management in therapeutic workplace	Therapeutic workplace	38	2
Dunn 2013	Psychosocial	Employment-based contingency	Prescription for naltrexone	67	2
Epstein 2009	Psychosocial	High/Low Dose Methadone maintenance therapy with vouchers	High/Low Dose Methadone maintenance therapy	252	2

Everly 2011	Psychosocial	Contingency Management in therapeutic workplace	Therapeutic workplace	35	2
Ghitza 2008	Psychosocial	Contingency Management	Methadone maintenance therapy	116	1
Gross 2006	Psychosocial	Contingency Management for vouchers OR medication	Buprenorphine Maintenance Therapy with counseling	60	2
Hser 2011	Psychosocial	Incentives	Usual Care	320	2
Iguchi 1997	Psychosocial	Contingency Management	Standard Treatment	103	1
Jiang 2012	Psychosocial	Contingency Management	Usual Care	160	2
Katz 2002	Psychosocial	Vouchers	No Vouchers	52	1
Kidorf 1996	Psychosocial	Contingency Management	Methadone maintenance therapy	16	2
Kidorf 2013	Psychosocial	Reinforced on-site integrated care	Standard care	125	2
Kosten 2003	Psychosocial	Contingency Management	Buprenorphine	160	2
Ling 2013	Psychosocial	Contingency Management + Buprenorphine-naloxone	Buprenorphine-naloxone	202	3
Milby 1978	Psychosocial	Contingency Management	Methadone maintenance therapy	75	2
Neufeld 2008	Psychosocial	Contingency Management	Methadone maintenance therapy	100	1
Oliveto 2005	Psychosocial	Contingency Management	Standard Treatment	140	2
Peirce 2006	Psychosocial	Contingency Management	Standard Care	388	2

Petry 2002	Psychosocial	Contingency Management	Standard Treatment	42	2
Petry 2005	Psychosocial	Contingency Management	Methadone maintenance therapy	77	3
Petry 2007	Psychosocial	Contingency Management	Methadone maintenance therapy	74	2
Preston 2000	Psychosocial	Contingency Management	Methadone maintenance therapy	120	3
Schottenfeld 2005	Psychosocial	Contingency Management (with buprenorphine or methadone)	Methadone maintenance therapy OR Buprenorphine Maintenance Therapy	162	3
Silverman 2004	Psychosocial	Contingency Management	Methadone maintenance therapy	78	3
Stitzer 1992	Psychosocial	Contingency Management	Methadone maintenance therapy	53	1
Marsch 2014	Psychosocial	Web-based education	Standard Counselling	160	1
Bickel 2008	Psychosocial	Therapist-delivered community reinforcement approach OR Computer-delivered community reinforcement approach	Standard treatment	135	2
Bell 2007	Witnessed Ingestion	Supervised buprenorphine-naloxone (daily, second-daily or thrice-weekly)	Weekly take-home dosing	119	2
Fiellin 2006**	Witnessed Ingestion	Enhanced medical management + thrice	Standard medical management + once	166	3

		weekly buprenorphine-naloxone dispensing	weekly buprenorphine-naloxone dispensing		
Holland 2012	Witnessed Ingestion	Twice weekly supervised methadone	Daily, unsupervised methadone	60	3
Holland 2014	Witnessed Ingestion	Supervised daily buprenorphine-naloxone	Unsupervised daily buprenorphine-naloxone	293	3
Rhoades 1998**	Witnessed Ingestion	Supervised methadone (5 days per week)	Supervised methadone (2 days a week)	107	1
Solhi 2016*	Comorbidities (Acute Pain)	Meperidine IV	Morphine IV	122	1
Blondell 2010*	Comorbidities (Chronic Pain)	Buprenorphine-Naloxone Steady Dose	Buprenorphine-Naloxone Tapering Dose	12	3
Wiest 2015*	Comorbidities (Chronic Pain)	Swedish massage	Treatment as usual	51	2
Neumann 2013*	Comorbidities (Chronic Pain)	Buprenorphine-Naloxone 4-16 mg/day	Methadone 10-60 mg/day	54	3
Stein 2012*	Comorbidities (Insomnia)	Trazodone	Placebo	137	4
McRae 2004	Comorbidities (Anxiety)	Buspirone	Placebo	36	5
Levin 2006*	Comorbidities (ADHD)	Sustained release methylphenidate or Sustained release bupropion	Placebo	97	4

Note: RCTs sufficiently described in systematic review were not included here.

* Study identified from RCT search.

** Study identified through grey literature search.